Estimated longevity benefit: +1.0 years. Evidence score: 100/100.
Nattokinase is a fibrinolytic enzyme derived from natto, a Japanese fermented soybean food. It has direct clot-dissolving activity in the bloodstream and is supported by multiple randomized controlled trials showing reductions in blood pressure and, in a large 1,062-person clinical study, significant regression of carotid arterial plaque and improvements in lipid parameters.
Nattokinase is a serine protease enzyme extracted from natto, a traditional Japanese food made from soybeans fermented with Bacillus subtilis. Unlike most dietary supplements that work through indirect metabolic pathways, nattokinase has direct fibrinolytic activity — it can break down fibrin clots in the bloodstream, an ability well-documented in human trials.
The most substantial human evidence comes from a 2022 clinical study published in Frontiers in Cardiovascular Medicine (Chen H et al., PMID 36072877) involving 1,062 participants across 11 Chinese medical centers. Over 12 months at 10,800 FU/day, participants showed significant reductions in carotid artery intima-media thickness and carotid plaque size. Lipid profile improvement rates ranged from 66.5 to 95.4% across measured parameters. Notably, a lower dose of 3,600 FU/day showed no benefit, indicating dose-dependence. The study also found additive effects when nattokinase was combined with vitamin K2 or low-dose aspirin.
Blood pressure evidence is supported by multiple randomized controlled trials. A 2023 meta-analysis of 6 RCTs including 546 participants (PMID 39076715) found nattokinase reduced systolic blood pressure by a mean of 3.45 mmHg (p<0.00001) and diastolic blood pressure by 2.32 mmHg (p<0.00001) versus placebo. A randomized double-blind North American trial in 74 participants with elevated blood pressure (PMID 27785095) confirmed diastolic blood pressure reduction from 87 to 84 mmHg (p<0.05) and significantly reduced von Willebrand factor — a validated cardiovascular risk marker — reinforcing both the antihypertensive and antithrombotic effects.
The antithrombotic mechanism has been directly demonstrated in a double-blind crossover RCT in 12 healthy men (Kurosawa Y et al., Sci Rep 2015, PMID 26109079). A single 2,000 FU oral dose produced measurable increases in D-dimer levels, decreases in Factor VIII activity, increases in antithrombin concentration, and prolongation of activated partial thromboplastin time — all within normal clinical ranges, confirming fibrinolytic activity without causing pathological anticoagulation.
Several limitations apply. Most clinical evidence is from Asian populations; the large 1,062-person study was a non-randomized clinical study, not a blinded RCT; the mechanistic fibrinolysis study involved only 12 participants; and no long-term mortality or cardiovascular event data exists for nattokinase. The enzyme's direct anticoagulant activity creates significant drug interaction risk with prescription anticoagulants such as warfarin, heparin, and direct oral anticoagulants — combinations that should not be attempted without specialist medical oversight.
Target Goal: The objective of nattokinase supplementation is to support cardiovascular health through improved blood fluidity, reduced fibrin accumulation, and maintained arterial compliance. The large clinical study demonstrating plaque and lipid benefits used 10,800 FU/day — a threshold that should be considered the minimum effective dose for arterial outcomes. Consistency over months is required; single-dose fibrinolytic effects are measurable within hours but structural arterial changes require sustained use. - Target dose: 10,800–15,000 FU/day, divided into 2-3 doses taken on an empty stomach - Lower doses (3,600 FU/day) have not demonstrated efficacy for atherosclerosis management - Look for products standardized in FU (fibrinolytic units) — the validated potency measure for nattokinase - NSK-SD (nattokinase with vitamin K2 removed) is the form used in most North American clinical trials and avoids unwanted K2 confounding
Dosage and Timing: Taking nattokinase on an empty stomach is important. The enzyme is a protein, and food in the stomach triggers digestive proteases that may degrade it before it reaches systemic circulation. The window of fibrinolytic activity after a dose lasts approximately 4-8 hours, which makes twice-daily dosing preferable to a single large dose. - 2,700–5,400 FU per capsule; aim for 2-3 capsules taken 2-3 times daily - Take 30 minutes before meals or at least 2 hours after meals - Morning dosing specifically targets the well-documented morning hypercoagulable state (peak clot risk between 6–10 am) - Common commercial format: 100 mg per capsule standardized to approximately 2,000 FU
Synergistic Combinations: The Chen 2022 study found that co-administration with aspirin and vitamin K2 produced additive effects on atherosclerosis management. These combinations should be considered thoughtfully given the overlapping anticoagulant and platelet-modulating mechanisms. - Vitamin K2 (MK-7 form, 100–200 mcg/day): directs calcium away from arterial walls; the Chen 2022 study documented synergistic effects on plaque outcomes - Low-dose aspirin: potential additive antithrombotic effect noted in clinical study, but increases bleeding risk — not recommended for self-directed use without physician guidance - Omega-3 fatty acids (EPA/DHA): complementary cardiovascular support through anti-inflammatory and lipid-modifying pathways; no direct interaction risk at standard doses
Contraindications and Drug Interactions: Nattokinase's direct fibrinolytic and anticoagulant activity makes it incompatible with several drug classes. These are not theoretical interactions — they arise from pharmacologically additive mechanisms that increase bleeding risk to clinically significant levels. - Do not combine with prescription anticoagulants: warfarin, heparin, apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa) - Use with caution alongside antiplatelet drugs: clopidogrel (Plavix), ticagrelor (Brilinta) — consult prescribing physician - Discontinue at least 7–14 days before any elective surgery; discuss timing with your surgeon - Contraindicated in active bleeding conditions, haemophilia, or recent haemorrhagic stroke - Not studied in pregnancy, breastfeeding, or individuals under 18
What to Monitor: Nattokinase's primary clinical endpoints — blood pressure and carotid artery intima-media thickness — are both measurable at home or through routine clinical tests. Tracking these periodically provides objective evidence of effect and helps identify the need to adjust dosing. - Blood pressure: home monitoring 3-4x/week; clinical trial data predicts ~3-5 mmHg systolic reduction with effective dosing - Carotid IMT: measurable by carotid ultrasound (available at many vascular clinics); primary structural endpoint from the 1,062-person study - Lipid panel (TC, LDL, HDL, TG): baseline measurement and recheck at 3-6 months; the Chen 2022 study documented improvements in multiple lipid parameters - Unexpected bruising, prolonged bleeding from minor cuts, or spontaneous bleeding are signs to reduce dose and seek medical advice
Supports
Ren N, Chen H, Li Y, McGrath R, Zhao Y
Meta-analysis of 6 RCTs (546 participants). Nattokinase significantly reduced systolic blood pressure by 3.45 mmHg (p<0.00001) and diastolic blood pressure by 2.32 mmHg (p<0.00001) versus placebo. No significant adverse events across all included studies.
View paperSupports
Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, Zhang X, Zeng J, Xu F, Lin Y
Clinical study in 1,062 participants across 11 medical centers. Nattokinase at 10,800 FU/day for 12 months produced significant reductions in carotid artery intima-media thickness and carotid plaque size. Lipid improvement rates ranged from 66.5 to 95.4%. Dose of 3,600 FU/day was ineffective. Additive effects noted with vitamin K2 and aspirin co-administration.
View paperSupports
Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, Inoue K, Park S, Jang Y, Lee JH
Randomized controlled trial demonstrating significant blood pressure reduction with nattokinase supplementation. Established nattokinase as an antihypertensive agent in a controlled human trial.
View paperSupports
Jensen GS, Lenninger M, Ero L, Benson KF
Double-blind RCT: 79 enrolled, 74 completed. North American subjects with elevated BP. 100 mg nattokinase daily for 8 weeks reduced diastolic BP from 87 to 84 mmHg (p<0.05) vs. placebo. Also significantly reduced von Willebrand factor, a validated cardiovascular risk marker. Confirmed blood pressure findings from Asian populations extend to a Western cohort.
View paperSupports
Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T
Double-blind crossover RCT in 12 healthy men. A single 2,000 FU oral dose of nattokinase significantly elevated D-dimer levels at 6 and 8 hours, decreased Factor VIII activity at 4 and 6 hours, increased antithrombin concentration at 2 and 4 hours, and prolonged activated partial thromboplastin time — all within normal clinical ranges. Directly demonstrates human fibrinolytic activity from a single oral dose.
View paper